EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study

Frits I Mulder, Noémie Kraaijpoel, Marc Carrier, Noori A Guman, Luis Jara-Palomares, Marcello Di Nisio, Walter Ageno, Jan Beyer-Westendorf, Frederikus A Klok, Thomas Vanassche, Hans-Martin B Otten, Benilde Cosmi und 15 weitere

Journal of Thrombosis and Haemostasis · 2023-04 · 21 (4) · 905-916

DOI: 10.1016/j.jtha.2023.01.003 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-04. Verfasst von Frits I Mulder und 26 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands; Department of Internal Medicine, Tergooi…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Neoplasms, Unknown Primary. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Trombosestichting Nederland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Platelet RNA sequencing has been shown to accurately detect cancer in previous studies. OBJECTIVES: To compare the diagnostic accuracy of platelet RNA sequencing with standard-of-care limited cancer screening in patients with unprovoked venous thromboembolism (VTE). METHODS: Patients aged ≥40 years with unprovoked VTE were recruited at 13 centers and followed for 12 months for cancer. Participants underwent standard-of-care limited cancer screening, and platelet RNA sequencing analysis was performed centrally at study end for cases and selected controls. Sensitivity and specificity were calculated, using the predefined primary positivity threshold of 0.54 for platelet RNA sequencing aiming at 86% test sensitivity, and an additional predefined threshold of 0.89 aiming at 99% test specificity. RESULTS: A total of 476 participants were enrolled, of whom 25 (5.3%) were diagnosed with cancer during 12-month follow-up. For each cancer patient, 3 cancer-free patients were randomly selected for the analysis. The sensitivity of limited screening was 72% (95% CI, 52-86) at a specificity of 91% (95% CI, 82-95). The area under the receiver operator characteristic for platelet RNA sequencing was 0.54 (95% CI, 0.41-0.66). At the primary positivity threshold, all patients had a positive test, for a sensitivity estimated at 100% (95% CI, 87-99) and a specificity of 8% (95% CI, 3.7-16.4). At the secondary threshold, sensitivity was 68% (95% CI, 48-83; p value compared with limited screening 0.71) at a specificity of 36% (95% CI, 26-47). CONCLUSION: Platelet RNA sequencing had poor diagnostic accuracy for detecting occult cancer in patients with unprovoked VTE with the current algorithm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsNeoplasms, Unknown PrimaryHumansEarly Detection of CancerProspective StudiesSequence Analysis, RNARisk Factors

Stichwörter der Autor:innen

blood plateletsearly detection of cancerneoplasmsthrombosistumor biomarkersvenous thromboembolism

Autor:innen und Institutionen

  • Amsterdam UMC location University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands; Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands; Amsterdam Cardiovascular Scienc…
  • Amsterdam UMC location University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, the Netherlands.
  • Department of Medicine, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Medical Surgical Unit of Respiratory Diseases, Virgen del Rocio Hospital, Seville, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
  • Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Förderung

  • Trombosestichting Nederland

Zitieren

APA

Mulder, F. I., Kraaijpoel, N., Carrier, M., Guman, N. A., Jara-Palomares, L., Di Nisio, M., Ageno, W., Beyer-Westendorf, J., Klok, F. A., Vanassche, T., Otten, H. B., Cosmi, B., Wolde, M. T., In 't Veld, S. G. J. G., Post, E., Ramaker, J., Zwaan, K., Peters, M., Delluc, A., …, & van Es, N. (2023). Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study. Journal of Thrombosis and Haemostasis, 21(4), 905-916. https://doi.org/10.1016/j.jtha.2023.01.003

Vancouver

Mulder FI, Kraaijpoel N, Carrier M, Guman NA, Jara-Palomares L, Di Nisio M, et al. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study. Journal of Thrombosis and Haemostasis. 2023;21(4):905-916. doi:10.1016/j.jtha.2023.01.003

BibTeX
@article{Mulder2023,
  author = {Mulder, Frits I and Kraaijpoel, Noémie and Carrier, Marc and Guman, Noori A and Jara-Palomares, Luis and Di Nisio, Marcello and Ageno, Walter and Beyer-Westendorf, Jan and Klok, Frederikus A and Vanassche, Thomas and Otten, Hans-Martin B and Cosmi, Benilde and Wolde, Marije Ten and In 't Veld, Sjors G J G and Post, Edward and Ramaker, Jip and Zwaan, Kenn and Peters, Mike and Delluc, Aurélien and Kamphuisen, Pieter W and Sanchez-Lopez, Veronica and Porreca, Ettore and Bossuyt, Patrick M M and Büller, Harry R and Wurdinger, Thomas and Best, Myron G and van Es, Nick},
  title = {Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {4},
  pages = {905--916},
  doi = {10.1016/j.jtha.2023.01.003}
}
Kostenlos starten →